Antigen Presentation – A Critical Step for Development of Immune Therapies, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, you will learn how a robust and industrialized mass spectrometry platform is used to directly observe and investigate MHC-presented and physiologically relevant peptides. The featured speaker will discuss how mass spectrometry is a key component of a successful immune therapy and vaccine development program requiring the identification of novel antigens.

Xtalks Life Science Webinars

This webinar will show examples of direct identification of novel presented peptides as well as survey the requirements for the industrialization of antigen presentation mass spectrometry to generate robust, reliable and quantitative measurements.

Antigen presentation is essential for the development of a robust immune response. The binding of an MHC-peptide complex by a T cell receptor is the initial and critical step for starting a new adaptive immune response or for regulating an ongoing one. Identification of effectively presented antigens is therefore a defining element for any successful immune therapy.

Direct observation of presented peptides by mass spectrometry has become required for novel epitope discovery. This approach is the most physiologically relevant way to detect the modified and unmodified peptides presented by any type of MHC. Additionally, mass spectrometry can be used to quantitate the peptide presentation to ensure that attractive targets are sufficiently expressed to trigger an immune reaction. The limiting factor has now become the quality of the mass spectrometry data generated.

This webinar will show examples of direct identification of novel presented peptides as well as survey the requirements for the industrialization of antigen presentation mass spectrometry to generate robust, reliable and quantitative measurements.

Designing a good immune therapy requires that an antigen is specific to the targeted pathology, as well as immunogenic. These factors are especially relevant for modern immune therapies that seek to engage the host response as part of the complete therapy. Antigen presentation by mass spectrometry should therefore be embedded in a broader, integrated, characterization of host immunity.

Specific characterizations include evaluation of wider host antigen presentation to assess target specificity, monitoring the status of the host microenvironment, as well as host immune exhaustion before and after antigen dosing to better understand the capacity to respond to the therapy.

Join Eustache Paramithiotis, PhD, Vice-President, Research & Development, Caprion Biosciences Inc. in a live webinar on Wednesday, June 10, 2020 at 10am EDT (3pm BST/UK).

For more information or to register for this event, visit Antigen Presentation – A Critical Step for Development of Immune Therapies.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website